Boehringer Ingelheim GmbH's Jardiance consolidated its position as the best-selling diabetes therapy in the selective sodium glucose cotransporter-2 (SGLT-2) inhibitor class in 2018 and the German group expects to keep hold of top spot with expanded indications in heart failure and kidney disease.
At its annual press conference in Ingelheim on 17 April, the company reported a rise of over 50% for Eli Lilly & Co.-partnered Jardiance (empagliflozin) to €1.5bn, while sales of Synjardy(empagliflozin/metformin) and Glyxambi (empagliflozin/linagliptin) added another €300m to BI's coffers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?